We assist cancer patients in receiving the optimal treatment medicine can offer. we leverage AI to detect, in real-time, a broad range of cancerous biomarkers and genomic insights from the biopsy image alone. By doing so, we overcome economical, logistical, and technological barriers to reach the full potential of personalized medicine for cancer patients.
Through global collaborations with top-tier medical centers and pharmaceutical companies, Imagene AI is revolutionizing molecular screening for both clinical practice and research.
Our success derives from our cutting-edge technology and talented multidisciplinary team of biologists, doctors, data scientists, software engineers, and business experts.
Imagene was established in 2020, by people who shared the same passion – to fulfill the potential of deep learning technology to simplify the process of matching the most effective treatment for each cancer patient.